产后溶血性尿毒症综合征诊治进展

发布时间：2018-03-06 23:22

  本文选题：产后溶血性尿毒症综合征　切入点：血栓性微血管疾病　出处：《实用妇产科杂志》2017年08期 　论文类型：期刊论文

【摘要】：产后溶血性尿毒症综合征(PHUS)属于血栓性微血管疾病,是非典型溶血性尿毒症综合征中的一种,主要临床表现为产后10周内发生不可逆急性肾功能衰竭伴血小板减少、微血管病性贫血,临床罕见,预后较差,少数病例发生于妊娠晚期。目前研究认为其发病的病理生理机制为原发性或继发性补体系统调节异常。早期诊断和及时治疗可以明显改善患者预后,但其诊断与鉴别诊断较为困难,目前仍以临床诊断为主,并应尽快启动诊断性治疗,特异性基因和分子检测有助于明确诊断。血液透析、血浆置换仍然是PHUS首选的治疗方法,而针对病因的特异性补体抑制剂可用于该病的长期治疗。
[Abstract]:Postpartum hemolytic uremia syndrome (PHUSS) belongs to thrombotic microvascular disease and is one of atypical hemolytic uremic syndrome. The main clinical manifestation is irreversible acute renal failure with thrombocytopenia within 10 weeks of postpartum. Microvascular anemia, rare clinical, poor prognosis, A few cases occur in late pregnancy. The pathophysiological mechanism of the disease is primary or secondary complement system regulation abnormality. Early diagnosis and timely treatment can significantly improve the prognosis of patients. But its diagnosis and differential diagnosis are more difficult. At present, it is still mainly clinical diagnosis, and should start diagnostic therapy as soon as possible. Specific gene and molecular detection is helpful to definite diagnosis. Hemodialysis and plasma exchange are still the preferred treatment methods for PHUS. The specific complement inhibitors can be used in the long-term treatment of the disease.
【作者单位】： 四川大学华西第二医院出生缺陷与相关妇儿疾病教育部重点实验室;四川省医学科学院四川省人民医院;
【分类号】：R714.46
，

本文编号：1576954